Indaptus Therapeutics is trading 6.77% down at $3.72 amid stock-specific volatility, with no new company-specific announcement or direct catalyst identified for September 23, 2026. - Shares gained 29.13% on September 22, 2026, following a highly volatile recent run. - The Nasdaq Composite is down 1.05%, while biotechnology is higher, suggesting broader-market weakness rather than sector weakness. - Financing news involving approximately $24 million was announced earlier.